Novartis chases new canakinumab niche after overall data failed to excite
admin 14th November 2017 Uncategorised 0Back in August, Novartis published findings from the phase 3 Cantos trial of Ilaris that weren’t “fully compelling to payers,” the company’s CEO-to-be, Vas Narasimhan, said on a Monday conference call. Now, Novartis is back with subgroup data for the proposed cardiovascular drug it thinks are more promising.
More: Novartis chases new canakinumab niche after overall data failed to excite
Source: fierce